Getting close...~6 months to the expected commissioning of the 5X PGX scale-up.
Currently CZO needs a 100X scale-up to get to a $40 million 1,000 L commercial PGX plant.
With a successful 5X scale-up it will only need a 20X scale-up to get to a 1,000 L plant.
That would appear a substantial decrease in the risk.
Commissioing of the 100 L scale-up is expected in Q3 2024.
CZO would then only need a 10X scale-up to a $40 million 1,000 L plant.
From requiring a 100X scale-up now to only requiring a 10X scale-up.
How should CZO play negotiations with potential licensees targeting the $4 billion CoQ10 market as risk is reduced from a 5X to 10X PGX scale-up? Should a partner target a bigger scale-up than a 1000 L plant in the $4 billion CoQ10 market? Potential partners are said to understand bioavailability as a unique selling point. CZO has smashed the gold standard in reported studies.
AGM notes:
Discussions concerning out-licensing a PGX complex are underway right now with serious potential partners in the neutraceutical industry. Partners are pretty impressed and understand why CZO wants to make bioavailability the unique selling point. Sigrun Watson is holding discussions with very, very serious partners. CoQ10 is a $4 billion market.